Substance Use Disorder

Neuromodulation for substance use disorder is investigational, not an established treatment. It is not first-line, is not a substitute for evidence-based addiction treatment and is relevant only to a small number of patients within specialized research settings.

Substance use disorder is a recognized medical condition affecting how a person’s brain responds to a substance, characterized by a pattern of use that continues despite significant harm, along with impaired control, craving, and, often, physical dependence. Established, effective treatments exist and remain the foundation of care: these include medication (such as buprenorphine, methadone or naltrexone, depending on the substance involved), structured counseling and behavioral therapies, and comprehensive addiction treatment programs, often combined for the best results.

For a small number of patients with severe substance use disorder that has not responded to comprehensive, appropriately delivered addiction treatment, researchers are studying neuromodulation approaches, including low-intensity focused ultrasound (LIFU), as a possible additional tool, targeting brain circuits involved in craving and reward. This research is at an early stage, and it should be understood as exactly that: research, not an established or routinely available treatment.

Before any discussion of neuromodulation, it is expected that a patient has engaged with, and had a genuine opportunity to benefit from, established addiction treatment appropriate to their situation, including medication where relevant, structured behavioral treatment, and comprehensive support addressing the many factors involved in recovery. Neuromodulation research is not presented as an alternative to this care and does not replace it.

Where a research program or specialized center is exploring neuromodulation for substance use disorder, evaluation is led jointly by addiction medicine or psychiatry and neurosurgery. It focuses on confirming the diagnosis and severity, documenting genuine engagement with and response to established treatment, assessing psychiatric and medical stability, and making sure the patient understands the investigational nature of the approach as part of informed consent.

Given the early stage of the evidence, this is considered only for adult patients with severe, disabling substance use disorder that has not responded to comprehensive established treatment, and only within a structured research or specialized program with appropriate oversight; not as a general clinical option offered outside that context.

Full technical detail on the technique itself; how it works, what distinguishes it from DBS and MRgFUS, and its general risk profile, is on our LIFU page. In the context of substance use disorder, research is exploring whether temporarily influencing activity in reward- and craving-related circuits can support recovery, alongside, not instead of, established addiction treatment and ongoing psychosocial support.

• Confirmation of diagnosis, severity and treatment history by an addiction medicine or psychiatric specialist
• Documentation of genuine engagement with established addiction treatment
• Assessment of psychiatric and general medical stability
• A clear discussion of the investigational nature of the approach and realistic expectations, as part of informed consent
• Ongoing coordination with the patient’s addiction treatment team throughout

Because this remains research, no specific outcome is promised, and it should not be understood as a proven path to recovery on its own. Where offered, it is framed honestly as a contribution to understanding whether this approach can help, alongside continued, established addiction treatment and support.

General risks of LIFU are described on its own page and are generally modest given its non-invasive, non-destructive nature. The most significant limitation is the evidence base itself; how much benefit it provides, for whom, and how durable any benefit is are all still being studied. Recovery from substance use disorder depends on many factors, and no single intervention, including this one, is presented as sufficient on its own.

Follow-up depends on the specific research program or specialized center involved and continues in close coordination with the patient’s addiction medicine and psychiatric team, alongside ongoing counseling and support.